Aurinia Pharmaceuticals Inc. Submits IND Application to US Food & Drug Administration for AUR 200

Aurinia Pharmaceuticals Inc. announced the submission of its Investigational New Drug application to the U.S. Food and Drug Administration for AUR200, a potential next generation therapy for B-cell...

Related Keywords

,Drug Administration ,Aurinia Pharmaceuticals Inc ,American College Of Rheumatology Convergence ,Aurinia Pharmaceuticals ,Investigational New Drug ,B Cell Activating Factor ,Proliferation Inducing Ligand ,American College ,Rheumatology Convergence ,Markets ,